IDE397
Source
AACR 2025 Garbett et al.
Publications
MTAP Pathway
Exploiting the dual metabolic vulnerabilities created by MTAP loss through a differentiated combination approach designed to drive deep and durable tumor responses.
KAT6/7
Targeting epigenetic vulnerabilities through dual inhibition of KAT6 and KAT7 to drive synthetic lethality in cancer.
IDE574
Source
AACR 2026 Gupta et al.
The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications
Read more (opens in a new tab)IDE574
Source
AACR 2025 Gupta et al.
